货号:A167476 同义名: ORI-9020;SB-9000
Inarigivir (ORI-9020;SB-9000) is a dinucleotide which can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Chronic hepatitis B virus infection (HBV) continues to pose a serious global health threat in many areas of the world, particularly in sub-Saharan Africa, the Western Pacific Region and areas of Eastern Europe[1]. Inarigivir, a novel dinucleotide, evaluated in transgenic mice expressing HBV, significantly reduced liver HBV DNA (P ≤ 0.001)[2]. The mode of antiviral action of Inarigivir appears to be direct interference of HBV replication at the level of HBV reverse transcriptase and/or DNA polymerase at an early step, either at, or prior to, the production of the first strand of HBV DNA. I.p. injection of Inarigivir at 100 mg/kg/day significantly reduced viral DNA in the liver (P ≤ 0.001) and showed anti-HBV activity similar to that of ADV. The minimal effective dosage of Inarigivir was identified to be between 1.6 and 0.5 mg/kg/day using liver HBV DNA values[2]. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT03493698 | Drug Interaction Potentiation | Phase 1 | Completed | - | Netherlands ... 展开 >> University Medical Center Groningen Groningen, Netherlands 收起 << |
NCT03434353 | Chronic Hepatitis b | Phase 2 | Recruiting | June 2020 | Hong Kong ... 展开 >> Alice Ho Miu Ling Nethersole Hospital Recruiting Hong Kong, Hong Kong Prince of Wales Hospital-HK Recruiting Hong Kong, Hong Kong Korea, Republic of Korea University Ansan Hospital Recruiting Ansan, Korea, Republic of, 425-707 Keimyung University Dongsan Medical Center Recruiting Daegu, Korea, Republic of, 41931 Kyungpook National University Hospital Recruiting Daegu, Korea, Republic of, 41944 Inje University Ilsan Paik Hospital Recruiting Ilsan, Korea, Republic of, 10380 Severance Hospital, Yonsei University Health System Recruiting Seoul, Korea, Republic of, 03722 Asan Medical Center Recruiting Seoul, Korea, Republic of, 05505 Gangnam Severance Hospital, Yonsei University Health System Recruiting Seoul, Korea, Republic of, 06273 Catholic University of Korea, Seoul Saint Mary's Hospital Recruiting Seoul, Korea, Republic of, 06591 SMG-SNU Boramae Medical Center Recruiting Seoul, Korea, Republic of, 07061 Korea University Guro Hospital Recruiting Seoul, Korea, Republic of, 08308 收起 << |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.70mL 0.34mL 0.17mL |
8.51mL 1.70mL 0.85mL |
17.02mL 3.40mL 1.70mL |
CAS号 | 475650-36-3 |
分子式 | C20H26N7O10PS |
分子量 | 587.5 |
别名 | ORI-9020;SB-9000 |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Keep in dark place,Inert atmosphere,2-8°C |
溶解度 |
DMSO: 190 mg/mL(323.4 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |